Maximal Oxygen Uptake (VO2max) in Patients With COPD - Trial NCT06257381
Access comprehensive clinical trial information for NCT06257381 through Pure Global AI's free database. This phase not specified trial is sponsored by Rigshospitalet, Denmark and is currently Recruiting. The study focuses on COPD. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Rigshospitalet, Denmark
Timeline & Enrollment
N/A
Feb 05, 2024
Oct 01, 2024
Primary Outcome
Between-day smallest real difference (SRD) for VO2 peak in COPD vs. healthy controls,Between-day coefficient of variance (CV) for VO2 peak in COPD vs. healthy controls (co-primary)
Summary
Patients with chronic obstructive pulmonary disease (COPD), facing a decline in lung function
 and compromised quality of life, often benefit from regular exercise (1). Assessing their
 cardiorespiratory fitness through maximal oxygen uptake (VO2max) is crucial (2), yet research
 on its validity and reliability in COPD patients remains sparse. This study aims to fill this
 gap, examining the content validity and test-retest reliability of the VO2-max test in COPD,
 comparing it with healthy controls.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06257381
Non-Device Trial